Free Trial
NASDAQ:MTSR

Metsera (MTSR) Stock Price, News & Analysis

Metsera logo
$22.74 -1.24 (-5.17%)
As of 04:00 PM Eastern

About Metsera Stock (NASDAQ:MTSR)

Key Stats

Today's Range
$21.90
$23.76
50-Day Range
$13.08
$30.33
52-Week Range
$12.30
$32.81
Volume
1.03 million shs
Average Volume
876,654 shs
Market Capitalization
$2.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00
Consensus Rating
Buy

Company Overview

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Receive MTSR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metsera and its competitors with MarketBeat's FREE daily newsletter.

MTSR Stock News Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Bank of America Securities Remains a Buy on Metsera, Inc. (MTSR)
Metsera reports Q4 EPS ($3.52) vs. (94c) last year
Metsera sees cash runway into 2027
See More Headlines

MTSR Stock Analysis - Frequently Asked Questions

Metsera's stock was trading at $29.50 at the beginning of the year. Since then, MTSR stock has decreased by 22.9% and is now trading at $22.74.
View the best growth stocks for 2025 here
.

Metsera, Inc. (NASDAQ:MTSR) posted its quarterly earnings data on Wednesday, March, 26th. The company reported ($3.52) EPS for the quarter.

Metsera (MTSR) raised $275 million in an initial public offering on Friday, January 31st 2025. The company issued 15,277,778 shares at a price of $18.00 per share.

Metsera's lock-up period expires on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the expiration of Metsera's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Top institutional shareholders of Metsera include Alphabet Inc. (4.72%), Massachusetts Financial Services Co. MA (0.46%), Jennison Associates LLC (0.34%) and Bank of New York Mellon Corp (0.03%).

Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
3/26/2025
Today
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MTSR
Previous Symbol
NASDAQ:MTSR
Web
N/A
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.00
High Stock Price Target
$56.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+96.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$2.52 billion
Optionable
N/A
Beta
N/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:MTSR) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners